Bevacizumab and wound-healing complications: Mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon

Annals of Plastic Surgery

Volumn 71, Issue 4, 2013, Pages 434-440

  Sharma, Ketan ^a   Marcus, Jeffrey R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Bevacizumab; Clinical evidence; Management guidelines; Mechanism of action; Toxicities; Wound healing complications

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; NEOPLASMS; PLASTIC SURGERY; SURGICAL WOUND DEHISCENCE; SURGICAL WOUND INFECTION; WOUND HEALING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; NEOPLASM; REVIEW; SURGICAL INFECTION; WOUND DEHISCENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; RECONSTRUCTIVE SURGICAL PROCEDURES; SURGICAL WOUND DEHISCENCE; SURGICAL WOUND INFECTION; WOUND HEALING;

EID: 84884700932     PISSN: 01487043     EISSN: 15363708     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31824e5e57     Document Type: Review

References (49)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182-1186
3. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52
4. Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis. 2002;5:237-256
5. Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(21 suppl 5): S21YS26
6. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004;38:1258-1264
7. Avastin (bevacizumab) package insert, 2008, Genentech, Inc: San Francisco
8. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43:490-501
9. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66:999-1013
10. Blowers E, Hall K. Adverse events in bevacizumab and chemotherapy: Patient management. Br J Nurs. 2009;18:424-428
11. Drinkwater SL, Smith A, Sawyer BM, et al. Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg. 2002;89:709-713
12. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: An important warning to all surgeons. Ann Plast Surg. 2009;62:707-709
13. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591
14. Bates DO, Jones RO. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds. 2003;2:107-120
15. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341: 738-746
16. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60:107-114
17. Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009;9:507-517
18. Pollack A. F.D.A. revokes approval of avastin for use as breast cancer drug. New York Times. 2011
19. Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol. 2006;18:316-320
20. Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw. 2008;6:53-57
21. Aragon-Ching JB, Dahut WL. The role of angiogenesis inhibitors in prostate cancer. Cancer J. 2008;14:20-25
22. Burger RA, SillMW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-5171
23. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186
24. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795
25. Lemmens L, Claes V, Uzzell M. Managing patients with metastatic colorectal cancer on bevacizumab. Br J Nurs. 2008;17:944-949
26. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91:173-180
27. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27:3385-3390
28. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist. 2009;14:862-870
29. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96-106
30. Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114:1609-1616
31. Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011; 18:733-737
32. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4076-4081
33. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonY small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191
34. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonYsmall-cell lung cancer. N Engl J Med. 2006;355: 2542-2550
35. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonYsmall-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8): 1227-1234
36. Bose D, Meric-Bernstam F, Hofstetter W, et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: Implications for patient care. Lancet Oncol. 2010;11:373-382
37. Cao Y, Tan A, Gao F, et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24:677-685
38. Finley D, Shen R, Rizvi A, et al. Operative outcomes using bevacizumab, docetaxel, and cisplatin as induction therapy in patients with operable lung cancer. Proc Am Soc Clin Oncol. 2009;27:abstr 7559
39. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-1835
40. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008; 26:5254-5260
41. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342
42. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27: 4733-4740
43. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156-163
44. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777
45. Forero-Torres A, Saleh MN, Galleshaw JA, et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptorpositive breast cancer. Clin Breast Cancer. 2010;10:275-280
46. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239-3247
47. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment ofmetastatic renal cell carcinoma: A randomised, doubleblind phase III trial. Lancet. 2007;370:2103-2111
48. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94-98
49. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181